GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NTRB · Oct 31, 2023

NutriBand Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001213900-23-095208General Corporate
Revenue growth14thOwn-history percentile · N=14
Evidence method

Yoy · gp.fundamentals.revenue

-30.77% · CORE · VALID

Inventory pressure92thOwn-history percentile · N=13
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

40.82% · OPTIONAL · VALID

Gross margin44thOwn-history percentile · N=18
Evidence method

Level · gp.fundamentals.gross_margin

37.14% · CORE · VALID

Operating margin22thOwn-history percentile · N=18
Evidence method

Level · gp.fundamentals.operating_margin

-402.84% · CORE · VALID

R&D intensityRAWCurrent state valid · history insufficient
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

128.90% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History29 statesHistory building
Period transition

What moved in the state?

Inventory Pressure Increased
Previous
23.92%
Current
40.82%
Delta
16.90%
Margin Decreased
Previous
45.69%
Current
37.14%
Delta
-8.54%
Profitability Decreased
Previous
-125.65%
Current
-402.84%
Delta
-277.19%
R And D Intensity Increased
Previous
67.86%
Current
128.90%
Delta
61.04%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.